Ultra-sensitivity Quantitative Fecal Immunochemical Test in Detecting Colorectal Advanced Adenoma and Colorectal Cancer
NCT ID: NCT04856423
Last Updated: 2021-09-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
6000 participants
OBSERVATIONAL
2021-04-19
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Real-time Automatic Quality Control System on Colorectal Adenoma Detection
NCT04901130
Efficacy Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia
NCT01767870
The Real-time Optical Diagnosis Value of Optical Enhancement Endoscopy in Colorectal Sessile Serrated Adenomas/Polyps
NCT03238573
Can Pan-Colonic Chromoendoscopy (PCC) Improve Adenoma Detection Rate in FIT-Positive-Patients: A Randomized Study
NCT04512612
Spectral Focused Imaging Versus White Light Imaging in Colorectal Adenoma Detection
NCT06603948
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Us-qFIT group
People in this group will detect fecal hemoglobin concentration by us-qFIT before colonoscopy.
The us-qFIT and colonoscopy with pathological examination
Detect fecal hemoglobin concentration by us-qFIT before colonoscopy, detect colon lesions using colonoscopy and pathological examination.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
The us-qFIT and colonoscopy with pathological examination
Detect fecal hemoglobin concentration by us-qFIT before colonoscopy, detect colon lesions using colonoscopy and pathological examination.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* People sign an "informed consent form"
Exclusion Criteria
* People with history of colorectal cancer;
* People with history of other diseases that may produce fecal blood, such as inflammatory bowel disease, ischemic enteritis, vascular alformation of intestine, intestinal tuberculosis or Non-Hodgkin's lymphoma involving digestive tract;
* People with symptoms including visible rectal bleeding, hematuria, hemorrhoid bleeds, severe and acute diarrhea and watery stool;
* People are in pregnancy, lactation or menstrual phase;
* People with severe congestive heart failure or other sever disease cause cannot tolerate colonoscopy.
50 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Tongji Hospital, Tongji University School of Medicine
OTHER
Tianjin Medical University General Hospital
OTHER
Binzhou Medical University
OTHER
Weihai Municipal Hospital
OTHER
People's Hospital of Lixia District of Jinan
UNKNOWN
Shandong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yanqing Li
Vice president of Qilu Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yanqing Li, PhD
Role: STUDY_CHAIR
Qilu Hospital, Shandong University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Binzhou Medical University Hospotal
Binzhou, Shandong, China
People's Hospital of Lixia District of Jinan
Jinan, Shandong, China
Qilu Hospital of Shandong University
Jinan, Shandong, China
Weihai Municipal Hospital
Weihai, Shandong, China
Shanghai Tongji Hospital, Tongji University School of Medicine
Shanghai, Shanghai Municipality, China
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Chengxia Liu
Role: primary
Hongjun LiZhang
Role: primary
Yanqing Li
Role: primary
Xiaozhong Gao
Role: primary
Shuzhang Xu
Role: primary
Bangmao Wang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020SDU-QILU-1026
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.